Carolyn F Deacon Selected Research

Dipeptidyl-Peptidase IV Inhibitors

11/2020	Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
1/2020	Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors.
12/2019	Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice.
1/2019	Effects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot Study.
1/2019	Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes.
1/2018	A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials.
1/2018	Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?
1/2018	Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.
1/2017	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite.
12/2016	Small Intestinal Glucose Delivery Affects the Lowering of Blood Glucose by Acute Vildagliptin in Type 2 Diabetes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carolyn F Deacon Research Topics

Disease

77	Type 2 Diabetes Mellitus (MODY) 10/2022 - 05/2002
9	Insulin Resistance 01/2020 - 08/2005
8	Hypoglycemia (Reactive Hypoglycemia) 01/2020 - 09/2004
7	Obesity 09/2021 - 02/2010
7	Hyperglycemia 01/2020 - 04/2009
7	Body Weight (Weight, Body) 03/2013 - 10/2002
5	Weight Loss (Weight Reduction) 01/2021 - 09/2004
5	Glucose Intolerance 04/2015 - 09/2004
4	Heart Failure 10/2022 - 01/2018
2	Overweight 05/2022 - 02/2011
2	Metabolic Diseases (Metabolic Disease) 01/2019 - 10/2015
2	Hyperlipidemias (Hyperlipidemia) 09/2018 - 01/2016
2	Chronic Renal Insufficiency 01/2018 - 03/2004
2	Diabetes Mellitus 04/2008 - 09/2006
2	Weight Gain 01/2008 - 09/2004
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2018
1	Kidney Diseases (Kidney Disease) 01/2018
1	Pancreatitis 12/2016
1	Hyperplasia 01/2016
1	Glucagonoma 01/2016
1	Inflammation (Inflammations) 09/2014
1	Chronic Kidney Failure (Chronic Renal Failure) 09/2014
1	Prediabetic State (Prediabetes) 03/2013
1	Chronic Pancreatitis 01/2009
1	Diarrhea 01/2009
1	Vomiting 01/2009
1	Nausea 01/2009
1	Hypoxia (Hypoxemia) 10/2008

Drug/Important Bio-Agent (IBA)

48	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2022 - 03/2004
48	Glucose (Dextrose)FDA LinkGeneric 10/2022 - 12/2003
28	IncretinsIBA 01/2022 - 03/2004
20	Insulin (Novolin)FDA Link 01/2022 - 04/2003
19	Dipeptidyl-Peptidase IV InhibitorsIBA 11/2020 - 04/2005
17	Hormones (Hormone)IBA 01/2020 - 11/2004
14	Glucagon (Glukagon)FDA Link 09/2021 - 01/2007
13	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2016 - 05/2002
11	VildagliptinIBA 12/2016 - 01/2007
10	Peptides (Polypeptides)IBA 05/2022 - 03/2004
8	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA 01/2022 - 12/2003
8	Metformin (Glucophage)FDA LinkGeneric 10/2020 - 01/2006
8	Sitagliptin Phosphate (Januvia)FDA Link 01/2018 - 11/2006
7	EnzymesIBA 01/2020 - 06/2004
6	Blood Glucose (Blood Sugar)IBA 01/2021 - 09/2004
5	Glucagon-Like Peptide-1 Receptor AgonistsIBA 12/2016 - 09/2007
5	Hypoglycemic Agents (Hypoglycemics)IBA 04/2011 - 09/2004
4	Glucagon-Like Peptides (Enteroglucagon)IBA 05/2022 - 03/2012
4	Proteins (Proteins, Gene)FDA Link 09/2018 - 04/2016
4	Dipeptidyl-Peptidases and Tripeptidyl-PeptidasesIBA 11/2016 - 01/2008
4	C-PeptideIBA 04/2013 - 05/2003
3	LinagliptinIBA 01/2022 - 01/2010
3	CarbohydratesIBA 10/2020 - 01/2018
3	Gastrointestinal Hormones (Hormones, Gastrointestinal)IBA 01/2018 - 03/2012
3	Liraglutide FDA Link 01/2017 - 10/2002
2	Neprilysin (Neutral Endopeptidase)IBA 10/2022 - 09/2021
2	sacubitril and valsartan sodium hydrate drug combinationIBA 10/2022 - 09/2021
2	Triglycerides (Triacylglycerol)IBA 05/2022 - 12/2018
2	Glucagon-Like Peptide-1 ReceptorIBA 01/2017 - 01/2016
2	XanthineIBA 11/2012 - 01/2010
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 04/2011 - 05/2009
1	Angiotensin Receptor AntagonistsIBA 10/2022
1	Pancreatic HormonesIBA 10/2022
1	Lipoproteins (Lipoprotein)IBA 05/2022
1	Peptide Hydrolases (Proteases)FDA Link 09/2021
1	SodiumIBA 01/2021
1	Pioglitazone (Actos)FDA Link 01/2020
1	Vasodilator Agents (Vasodilators)IBA 01/2019
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2019
1	Nonesterified Fatty Acids (NEFA)IBA 12/2018
1	Fatty Acids (Saturated Fatty Acids)IBA 12/2018
1	Dietary Carbohydrates (Carbohydrate, Dietary)IBA 09/2018
1	Cholecystokinin (Pancreozymin)IBA 09/2018
1	Biological ProductsIBA 01/2018
1	Amylases FDA Link 12/2016
1	Lipase (Acid Lipase)FDA Link 12/2016
1	OxyntomodulinIBA 05/2016
1	Therapeutic UsesIBA 01/2016
1	Glucagon Receptors (Glucagon Receptor)IBA 01/2016
1	Amino Acids FDA Link 01/2016
1	exendin (9-39)IBA 01/2016
1	Atropine FDA LinkGeneric 09/2015
1	Cell Adhesion MoleculesIBA 09/2014
1	GlucocorticoidsIBA 04/2013
1	Prednisolone (Predate)FDA LinkGeneric 04/2013
1	Arginine (L-Arginine)FDA Link 04/2013
1	Pharmaceutical PreparationsIBA 03/2013
1	Coffee FDA Link 02/2011
1	trigonellineIBA 02/2011
1	Chlorogenic AcidIBA 02/2011
1	saxagliptin FDA Link 05/2009
1	LeptinIBA 10/2008
1	Oxygen (Dioxygen)IBA 10/2008

Therapy/Procedure

11	Therapeutics 01/2018 - 12/2004
4	Intravenous Infusions 01/2018 - 12/2003
4	Gastric Bypass (Roux-en-Y Gastric Bypass) 11/2017 - 09/2014
3	Aftercare (After-Treatment) 01/2022 - 07/2007
3	Glycemic Control 11/2012 - 02/2008
2	High-Protein Diet 10/2020 - 01/2018
2	Oral Administration 01/2018 - 01/2007
1	Vagotomy 09/2014